Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Crispr rapeutics - The Untold Story

Here are the 5 biggest innovations to expect in 2023

Inverse predicts the biggest innovations of 2023, including wins in renewable energy, electric vehicles, and biotechnology.

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022

CRISPR, 10 Years On: Learning to Rewrite the Code of Life

CRISPR, 10 Years On: Learning to Rewrite the Code of Life

Ten years ago this week, Jennifer Doudna and her colleagues published the results of a test-tube experiment on bacterial genes. When the study came out in the journal Science on June 28, 2012, it did not make headline news. In fact, over the next few weeks, it did not make…

Asharq Al-Awsat

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Evercore ISI Group Downgrades CRISPR Therapeutics: Here's What You Need To Know

Evercore ISI Group downgraded its rating of CRISPR Therapeutics (NASDAQ:CRSP) to In-Line with a price target of $60.00, changing its price target from $66.00 to $60.00. Shares of CRISPR Therapeutics are trading up 3.81% over the last 24 hours, at $62.23 per share.

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022

Why CRISPR Therapeutics Stock Is Falling

CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading lower Wednesday after several analysts adjusted price targets on the stock following the company's Innovation Day.

Chardan Capital Maintains Buy Rating for CRISPR Therapeutics: Here's What You Need To Know

Chardan Capital has decided to maintain its Buy rating of CRISPR Therapeutics (NASDAQ:CRSP) and lower its price target from $168.00 to $164.00. Shares of CRISPR Therapeutics are trading down 8.24% over the last 24 hours, at $59.34 per share.

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Reason Why This Analyst Says CRISPR Therapeutics Is A Biotech Winner

3 Reason Why This Analyst Says CRISPR Therapeutics Is A Biotech Winner

CRISPR Therapeutics AG (NASDAQ: CRSP) has a diversified pipeline with potential CTX001 commercialization and CTX110 potential approval expected in 2024, according to BMO Capital Markets.

Analyst Ratings for CRISPR Therapeutics

Analyst Ratings for CRISPR Therapeutics

CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter:

$100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much

$100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.5% on an annualized basis producing an average annual return of 25.08%. Currently, CRISPR Therapeutics has a market capitalization of $4.02 billion.

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022

What 4 Analyst Ratings Have To Say About CRISPR Therapeutics

What 4 Analyst Ratings Have To Say About CRISPR Therapeutics

Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings:

$1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much

$1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.85% on an annualized basis producing an average annual return of 28.2%. Currently, CRISPR Therapeutics has a market capitalization of $4.51 billion.

Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today

Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 26.02%. Currently, CRISPR Therapeutics has a market capitalization of $5.12 billion.

Get all your
news in one place.

100's of premium titles.
One news app.

1

People

Jennifer Doudna

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Harvard University

Southwest Airlines

Palantir Technologies

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play